Astellas and LabCentral Announce Golden Ticket Winners

CAMBRIDGE, Mass., Oct. 8, 2020 /PRNewswire/ — Astellas Venture Management LLC (President: Kazunori Maruyama, Ph.D., “AVM”), a wholly-owned venture capital subsidiary of Astellas Pharma Inc., and LabCentral, a launchpad for early-stage life-sciences startups, today announced AXONIS Therapeutics, Inc. and Tenza as the winners of the Astellas-sponsored “Golden Ticket Competition”. A Golden Ticket award offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral’s state-of-the-art lab facility in Cambridge, Massachusetts, as well as access to Astellas’ research and development (R&D) capabilities and business leaders.

AXONIS and Tenza were chosen for the strength of the innovation in their approach, the therapeutic potential of their research and alignment of their novel technological platforms with Astellas’ research and development (R&D) Focus Areas.

“In awarding these Golden Tickets, we are reinforcing Astellas’ ongoing commitment to discovering and advancing innovative science for the potential future benefit of patients worldwide,” said Maruyama, President, AVM. “We applaud

Read More
Read More